Prospective study of Sofosbuvir/Ribavirin for HCV genotype 2 infected Japanese patients

Prospective study of Sofosbuvir/Ribavirin for HCV genotype 2 infected Japanese patients - IFN free SR study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000019399

Enrollment

250

Registered

2015-11-01

Start date

2015-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genotype 2 infected chronic liver diseases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HCV genotype 2 infected patients with chronic liver disorders. Patients satisfied the public indication for sofosbuvir and ribavirin

Exclusion criteria

Exclusion criteria: Pregnant women Decompensated cirrhosis Hepatocellular carcinoma Renal impairment (eGFR<30) Doctors judge as inappropriate

Design outcomes

Primary

Measure	Time frame
sustained viral response	—

Secondary

Measure	Time frame
Suppression of hepatocarcinogenesis	—

Countries

Japan

Contacts

Public ContactAkihiro Tamori

Osaka City University Graduate School of Medicine Department of Hepatology

atamori@med.osaka-cu.ac.jp06-6645-3811

Outcome results